Jazz Pharmaceuticals PLC (JAZZ): prezzo delle azioni e notizie

JAZZ:NASDAQ

Jazz Pharmaceuticals PLC

229,85 USD

-0,17%

(-0,40) 1G

229,85 USD

0,00% (0,00)

After Hours

Chiusura: 24 giu, 16:00:01 GMT-4 · USD

Tutti i simboli

YTD

MAX

	Simbolo	Prezzo	Cambio	% di cambio

Generazione degli approfondimenti principali per JAZZ in corso…

Apertura

229,76 USD

Massimo

234,08 USD

Minimo

228,30 USD

Cap. mercato

14,43 Mld

Vol. medio

932,65K

Volume

719,88K

Rapporto P/E

2.161,46

Max 52 sett.

243,32 USD

Min 52 sett.

105,00 USD

Utili per azione

0,11 USD

Beta

0,32

Azioni in circolazione

62,82 Mln

N. di dipendenti

Apertura

229,76 USD

Massimo

234,08 USD

Minimo

228,30 USD

Cap. mercato

14,43 Mld

Vol. medio

932,65K

Volume

719,88K

Rapporto P/E

2.161,46

Max 52 sett.

243,32 USD

Min 52 sett.

105,00 USD

Utili per azione

0,11 USD

Beta

0,32

Azioni in circolazione

62,82 Mln

N. di dipendenti

Azioni correlate

Innovative Industrial Properties Inc

61,08 USD

+0,69%

Articoli giornalistici

Da fonti sul web

Yahoo Finance

6 ore fa

Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts

The Motley Fool

1 giorno fa

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks

Profilo

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia

Informazioni su Jazz Pharmaceuticals PLC

CEOBruce C Cozadd

Dipendenti2,89K

Data di fondazione2003

Sede-

Settore-

Sito webjazzpharma.com

Analista	Consiglio	Azione	Prezzo target	Proiezione	Data
Gregory Renza Truist Financial	Buy	Maintained	-	-	06/18/2026
Unknown Analyst Jefferies	Buy	Maintained	265,00 USD	+15,3%	06/16/2026
David Amsellem Piper Sandler	Buy	Reiterated	301,00 USD	+31%	06/16/2026
Joseph Thome TD Cowen	Buy	Maintained	275,00 USD	+19,6%	06/12/2026
Jason Gerberry Bank of America Securities	Buy	Reiterated	307,00 USD	+33,6%	06/10/2026
Joon Lee Truist Financial	Buy	Initiated	256,00 USD	+11,4%	06/09/2026
Jeffrey Walch Bernstein	Hold	Reiterated	229,00 USD	-0,4%	06/08/2026
Unknown Analyst Bernstein	Hold	Maintained	-	-	06/01/2026
Jessica Fye J.P. Morgan	Buy	Maintained	-	-	06/02/2026
Etzer Darout Barclays	Buy	Reiterated	253,00 USD	+10,1%	05/27/2026
Unknown Analyst J.P. Morgan	Buy	Maintained	265,00 USD	+15,3%	05/20/2026
Ashwani Verma UBS	Buy	Upgraded	307,00 USD	+33,6%	05/19/2026
Ami Fadia Needham	Buy	Reiterated	255,00 USD	+10,9%	05/11/2026
Brian Skorney Robert W. Baird	Buy	Maintained	252,00 USD	+9,6%	05/06/2026
Tiago Fauth Raymond James	Buy	Maintained	239,00 USD	+4%	05/06/2026
Leonid Timashev RBC Capital	Buy	Reiterated	258,00 USD	+12,2%	05/06/2026
Annabel Samimy Stifel Nicolaus	Buy	Reiterated	230,00 USD	+0,1%	05/06/2026
Mohit Bansal Wells Fargo	Buy	Maintained	265,00 USD	+15,3%	05/06/2026
Sean Laaman Morgan Stanley	Buy	Maintained	245,00 USD	+6,6%	05/05/2026
Unknown Analyst Raymond James	Buy	Maintained	239,00 USD	+4%	05/06/2026
David Hoang Deutsche Bank	Buy	Maintained	226,00 USD	-1,7%	03/05/2026

Tutti i valori in USD	giu 2025	set 2025	dic 2025	mar 2026
Fatturato	1,05 Mld	1,13 Mld	1,20 Mld	1,07 Mld
Costo dei beni venduti	116,27 Mln	128,88 Mln	112,92 Mln	96,60 Mln
Costo del venduto	116,27 Mln	128,88 Mln	112,92 Mln	96,60 Mln
Spese di ricerca e sviluppo	189,97 Mln	198,20 Mln	172,66 Mln	196,00 Mln
Spese totali per ricerca e sviluppo	-	-	-	-
Spese di vendita, generali e amministrative	358,40 Mln	379,15 Mln	418,46 Mln	352,70 Mln
Spese operative	710,47 Mln	745,72 Mln	760,86 Mln	721,00 Mln
Spese operative totali	826,74 Mln	874,60 Mln	873,79 Mln	817,60 Mln
Reddito operativo	218,97 Mln	251,51 Mln	324,14 Mln	251,30 Mln
Altri redditi non operativi	-	-	-	122,80 Mln
EBT inclusi elementi straordinari	-735,64 Mln	8,99 Mln	208,41 Mln	299,20 Mln
EBT esclusi elementi straordinari	169,72 Mln	202,99 Mln	278,02 Mln	336,70 Mln
Spese per imposte sul reddito	-17,17 Mln	-242,42 Mln	4,96 Mln	6,10 Mln
Aliquota fiscale effettiva	2,33%	-2.697,20%	2,38%	2,04%
Altre spese operative	-	-	-	-
Risultato netto	-718,47 Mln	251,41 Mln	203,45 Mln	293,10 Mln
Margine di profitto netto	-68,71%	22,33%	16,98%	27,42%
Utili per azione	-8,25	8,13	6,64	6,34
Interessi e reddito da investimento	19,10 Mln	18,60 Mln	20,50 Mln	23,40 Mln
Interesse passivo	-66,46 Mln	-67,18 Mln	-65,91 Mln	-63,30 Mln
Interessi passivi netti	-47,36 Mln	-48,58 Mln	-45,41 Mln	-39,90 Mln
Addebiti per ammortamento e svalutazione	-	-	-	-
EBITDA	392,98 Mln	429,76 Mln	503,31 Mln	432,70 Mln
Utile o perdita derivante dalla vendita di asset	-	-	-	-

I contenuti creati con l'AI potrebbero contenere errori. Scopri di più

AssistenzaInvia feedbackPrivacy Termini Disclaimer

Google Finanza

Ricerca